WUHAN YZY BIOPHARMA CO., LTD. Wuhan YZY Biopharma Co., Ltd. Share Price
Equities
2496
CNE1000063C4
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.45 HKD | 0.00% |
|
0.00% | -16.29% |
| Sales 2021 | 12.16M 1.68M 13.15M 134M | Sales 2022 | 2.28M 315K 2.46M 25.16M | Capitalization | 1.34B 185M 1.44B 14.76B |
|---|---|---|---|---|---|
| Net income 2021 | -149M -20.62M -161M -1.65B | Net income 2022 | -189M -26.16M -204M -2.09B | EV / Sales 2021 * | - |
| Net cash position 2021 * | - 0 0 0 | Net cash position 2022 * | - 0 0 0 | EV / Sales 2022 * | - |
| P/E ratio 2021 * |
-
| P/E ratio 2022 * |
-
| Employees | 123 |
| Yield 2021 * |
-
| Yield 2022 * |
-
| Free-Float | 58.72% |
More Fundamentals
* Assessed data
More news
| 1 month | -3.25% | ||
| 3 months | -12.56% | ||
| 6 months | -12.35% | ||
| Current year | -16.29% |
1 week
7.45
7.45
1 month
7.457.70
Current year
7.458.96
1 year
7.4519.80
3 years
7.4519.80
5 years
7.4519.80
10 years
7.4519.80
Wuhan YZY Biopharma Co Ltd is a China-based company principally engaged in the research, development, production and sales of pharmaceuticals. The Company is mainly engaged in the research, development and industrialization of bispecific antibody drugs. The Company's main products include anti-PD1&anti-CD3, anti-CD19&anti-CD3, and anti-CDX&CD3. The Company's drug products are mainly used in major diseases such as tumor, immunity, inflammation, cardiovascular and infection.
| 1st Jan change | Capi. | |
|---|---|---|
| -16.29% | 185M | |
| +3.91% | 108B | |
| +10.87% | 104B | |
| +1.28% | 22.33B | |
| -13.14% | 22.19B | |
| -7.05% | 18.69B | |
| -38.36% | 17.74B | |
| -10.66% | 17.64B | |
| +3.75% | 14.05B | |
| +36.70% | 12.51B |
- Stock Market
- Equities
- 2496 Stock
